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Signi cance of Atrial Tachycardia. Introduction: The purpose of this prospective study was to
determine the prevalence and clinical signi cance of inducible atrial tachycardia in patients undergoing
slow pathway ablation for AV nodal reentrant tachycardia who did not have clinically documented
episodes of atrial tachycardia.
Methods and Results: Twenty-seven (15%) of 176 consecutive patients who underwent slow pathway
ablation for AV nodal reentrant tachycardia were found to have inducible atrial tachycardia with a mean
cycle length of 351 6 95 msec. The atrial tachycardia was sustained in 7 (26%) of 27 patients and was
isoproterenol dependent in 20 patients (74%). The atrial tachycardia was not ablated or treated with
medications, and the patients were followed for 9.7 6 5.8 months. Six (22%) of the 27 patients experienced
recurrent palpitations during follow-up. In one patient each, the palpitations were found to be due to
sustained atrial tachycardia, nonsustained atrial tachycardia, recurrence of AV nodal reentrant tachy-
cardia, paroxysmal atrial  brillation, sinus tachycardia, and frequent atrial premature depolarizations.
Thus, only 2 (7%) of 27 patients with inducible atrial tachycardia later developed symptoms attributable
to atrial tachycardia.
Conclusion: Atrial tachycardia may be induced by atrial pacing in 15% of patients with AV nodal
reentrant tachycardia. Because the vast majority of patients do not experience symptomatic atrial
tachycardia during follow-up, treatment for atrial tachycardia should be deferred and limited to the
occasional patient who later develops symptomatic atrial tachycardia. (J Cardiovasc Electrophysiol,Vol. 12,
pp. 507-510, May 2001)
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Introduction
During electrophysiologic testing in patients with AV
nodal reentrant tachycardia, atrial tachycardia sometimes is
induced by atrial pacing. In patients without clinically doc-
umented episodes of atrial tachycardia, the clinical signi -
cance of inducible atrial tachycardia may be uncertain.
Therefore, it often is unclear whether treatment of the atrial
tachycardia is necessary. The purpose of this prospective
study was to determine the prevalence and clinical signi -
cance of atrial tachycardia induced in patients undergoing
radiofrequency ablation for AV nodal reentrant tachycardia.
Methods
Characteristics of the Study Population
The subjects of this study were 176 consecutive patients
(130 women [74%] and 46 men; mean age 48 6 17 years)
referred to the University of Michigan Medical Center for
radiofrequency ablation of paroxysmal supraventricular
tachycardia found to be caused by AV nodal reentrant
tachycardia. None of these patients had prior ECG record-
ings suggestive of atrial tachycardia. Twenty-six patients
(15%) had underlying heart disease (coronary artery disease
15, valvular heart disease 7, dilated cardiomyopathy 3, and
hypertrophic cardiomyopathy1). Mean left ventricular ejec-
tion fraction was 0.58 6 0.05, and mean left atrial diameter
was 36 6 7 mm.
Electrophysiologic Testing
In all patients, antiarrhythmic drug therapy was discon-
tinued at least  ve half-lives before the procedure. After
obtaining informed consent and with the patients in a fasting
state, three quadripolar electrode catheters were inserted
into a femoral vein and positioned in the high right atrium,
His-bundle position, and right ventricular apex. Several
ECG leads and the intracardiac electrograms were displayed
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on an oscilloscope and recorded on optical disk (EPMed-
Systems, Mount Arlington, NJ, USA). Pacing was per-
formed at twice the pacing threshold using a programmable
stimulator (EPMedSystems).
Study Protocol
During the electrophysiologic procedure, incremental
atrial and ventricular pacing and atrial and ventricular pro-
grammed stimulation with up to three extrastimuli were
performed to induce tachycardia. If these maneuvers did not
result in arrhythmia induction, they were repeated during
infusion of isoproterenol 1 to 4 mg/min. AV nodal reentrant
tachycardia was induced in all patients. After slow pathway
ablation, which was successful in all patients, the same
pacing maneuvers were used to con rm successful elimina-
tion of the AV nodal reentrant tachycardia.
Because short episodes of inducible atrial tachycardia are
often likely to be a nonspeci c response to atrial stimula-
tion, for the purposes of the present study, inducible atrial
tachycardia was de ned as a monomorphic atrial tachycar-
dia that had cycle length , 600 msec and duration . 5
seconds, and was reproducibly inducible (Fig. 1). The fol-
lowing criteria were used to diagnose atrial tachycardia: (1)
induction by an atrial depolarization that blocked in the AV
node; (2) induction independent of a critical atrial-His in-
terval; (3) eccentric atrial activation; (4) a variable VA
relationship during tachycardia; (5) failure to terminate the
tachycardia by ventricular pacing without advancing the
atrial electrograms; (6) a “V-A-A” response upon cessation
of pacing after entrainment with ventricular pacing1 ; and (7)
when the tachycardia was nonsustained, consistent sponta-
neous termination in the absence of AV block. The atrial
tachycardia was considered sustained if its duration was
. 30 seconds.
None of 27 patients who had inducible atrial tachycardia
initially were treated for the tachycardia with either radio-
frequency catheter ablation or antiarrhythmic drug therapy.
However, 6 (22%) of these patients were treated with ve-
rapamil, atenolol, or  ecainide for hypertension, inappro-
priate sinus tachycardia, or paroxysmal atrial  brillation.
The patients were seen in an outpatient clinic 4 months
after the electrophysiologic procedure and were told to
contact one of the authors in the event of a recurrence of
palpitations. In the event of recurrent symptoms, the patient
was provided with a continuous-loop event monitor to doc-
ument the rhythm at the time of symptoms. Mean duration
of follow-up was 9.7 6 5.8 months (range 1.1 to 19).
Statistical Analysis
Continuous variables are expressed as mean 6 1 SD.
Comparisons were performed with Student’ s t-test or the
Fisher exact test. P , 0.05 was considered signi cant.
Results
Prevalence of Induced Atrial Tachycardia
Among the 176 patients, 27 patients (15%) had inducible
atrial tachycardia. Age, gender, ejection fraction, left atrial
diameter, and prevalence of structural heart disease did not
differ signi cantly between patients with and patients with-
out inducible atrial tachycardia (Table 1).
Figure 1. Example of sustained atrial tachycardia (cycle length 540 msec, duration 40 sec) induced by programmed atrial stimulation with a single
extrastimulus. Displayed are leads I, II, III, V1, and V5, an electrogram recorded at the high right atrium (HRA), the distal (d), medial (m), and proximal
(p) His-bundle electrograms (HIS), right ventricular electrogram (RVA), and stimulus marker (STIM).
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Characteristics of Induced Atrial Tachycardia
Among the 27 patients with inducible atrial tachycardia,
the tachycardia was nonsustained in 20 patients (74%) and
was inducible only during isoproterenol infusion in 20 pa-
tients (74%). Mean tachycardia cycle length was 350 6 117
msec for the sustained episodes and 352 6 89 msec for the
nonsustained episodes (P 5 1.0). The sustained episodes
had a mean duration of 107 6 96 seconds, and the nonsus-
tained episodes had a mean duration of 10 6 8 seconds (P ,
0.001). The sustained episodes were terminated by atrial
overdrive pacing in 2 of 7 patients and terminated sponta-
neously after 30 seconds in the remaining patients.
Atrial tachycardia was induced by right atrial overdrive
pacing in 8 patients, right ventricular overdrive pacing in 2,
programmed atrial stimulation with a single extrastimulus in
11, programmed atrial stimulation with two extrastimuli in
5, and programmed ventricular stimulation with a single
extrastimulus in 1.
Recurrent Palpitations
Six (22%) of the 27 patients with inducible atrial tachy-
cardia had recurrent symptoms of palpitations after success-
ful ablation of AV nodal reentrant tachycardia. The palpi-
tations occurred at 108 6 123 days of follow-up (range 14
to 350) and were described as being similar to the palpita-
tions experienced before the ablation procedure by 1 patient
and as different from the palpitations experienced before the
ablation procedure by 5. Four patients had palpitations
lasting . 30 seconds, and 2 patients had episodes lasting
, 30 seconds.
ECG documentation with a continuous-loop event re-
corder demonstrated a probable atrial tachycardia in two
patients (sustained in one and nonsustained in the other)
(Fig. 2). In both cases, the documented atrial tachycardia
had a cycle length similar to the induced episode (540 vs
480 msec, and 440 vs 460 msec). One patient had a record-
ing consistent with AV nodal reentrant tachycardia (con-
 rmed by repeat electrophysiologic procedure), 1 had inap-
propriate sinus tachycardia, 1 had paroxysmal atrial
 brillation, and 1 had frequent premature atrial complexes
(Table 2).
Among the 27 patients with inducible atrial tachycardia,
the tachycardia was sustained and inducible in the absence
of isoproterenol in 4 patients. These characteristics were not
predictive of recurrent palpitations after slow pathway ab-
lation. Three of these 4 patients remained asymptomatic
during follow-up, and only 1 (25%) experienced symptom-
atic sustained atrial tachycardia during follow-up. Among
the 23 patients in whom inducible atrial tachycardia was not
sustained and isoproterenol dependent, 1 patient (4%) ex-
perienced symptomatic atrial tachycardia (nonsustained)
during follow-up (P 5 0.3). The patient with sustained atrial
tachycardia was treated with propafenone, and the patient
with nonsustained atrial tachycardia was treated with ateno-




The results of this study demonstrate that atrial tachy-
cardia may be inducible in 15% of patients who undergo
radiofrequency ablation of AV nodal reentrant tachycardia
and who do not have prior clinical documentation of atrial
tachycardia. The majority of the episodes of inducible atrial
tachycardia induced in this study were nonsustained and
isoproterenol dependent. Fewer than 10% of the patients in
whom atrial tachycardia was induced later experienced
symptoms attributable to atrial tachycardia. This observa-
tion suggests that inducible atrial tachycardia, even when
monomorphic and reproducibly inducible, often may be a
nonspeci c  nding that does not have clinical signi cance.
Therefore, when atrial tachycardia is inducible in a patient
with AV nodal reentrant tachycardia who does not have
documentation of prior atrial tachycardia, therapy directed
at the atrial tachycardia should be deferred and limited to
the occasional patient who later develops symptomatic atrial
tachycardia.
TABLE 1








No. of patients 27 (15%) 149 (85%)
Age (years) 49 6 15 48 6 18 0.9
Ejection fraction 0.59 6 0.03 0.58 6 0.06 0.3
Left atrial diameter (mm) 36 6 5 36 6 7 0.8
Female gender 21 (78%) 109 (73%) 0.4
Heart disease 4/27 (15%) 22/149 (15%) 0.6
Continuous values are expressed as mean 6 SD.
Figure 2. Recording obtained with a continuous-loopevent recorder at the
time of palpitations 20 days after successful slow pathway ablation in the
same patient who had the inducible atrial tachycardia shown in Figure 1.
The cycle length of this tachycardia is 480 msec, and the tracing is
suggestive of an atrial tachycardia. The recordings are continuous, with
the top strip displaying probable atrial tachycardia, the middle strip
showing spontaneous conversion to sinus rhythm, and the bottom strip
showing the artifact caused by activation of the recorder by the patient.
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Tachycardia Substrate
AV nodal reentrant tachycardia and accessory pathway
tachycardias have a clearly de ned anatomic substrate that
gives rise to reentrant tachycardias and are amenable to
radiofrequency catheter ablation.2 However, in the case of
atrial tachycardia, the underlying tachycardia mechanism
may be reentry, abnormal automaticity, or triggered activ-
ity.3 The atrial tachycardias induced in the present study
were inducible by pacing maneuvers, consistent with either
reentry or triggered activity. These types of atrial tachycar-
dia may not require a speci c anatomic substrate, which
explains why they may often represent a nonspeci c  nd-
ing.
Previous Studies
Previous studies showed that symptomatic palpitations
after slow pathway ablation for AV nodal reentrant tachy-
cardia, or after accessory pathway ablation, occur in 32% to
36% of patients.4 ,5 Atrial tachycardia was found to be the
cause of recurrent palpitations in , 5% of the patients who
had recurrent symptoms. The low incidence of recurrent
palpitations attributable to atrial tachycardia after catheter
ablation of AV nodal reentrant tachycardia or of an acces-
sory pathway in these two prior studies is consistent with
the results of the present study.
In this series, 7 (26%) of the 27 patients who underwent
successful slow pathway ablation were treated during fol-
low-up with an antiarrhythmic drug for paroxysmal atrial
 brillation, atrial tachycardia, or inappropriate sinus tachy-
cardia. This is similar to the results of a prior study in which
17% of 398 patients who underwent successful accessory
pathway ablation were treated with an antiarrhythmic med-
ication during follow-up.6
Limitations
Some of the patients who had inducible atrial tachycardia
may have had asymptomatic recurrences of atrial tachycar-
dia during follow-up. Therefore, the predictive value of
inducible atrial tachycardia may have been underestimated.
However, if episodes of atrial tachycardia during follow-up
are asymptomatic, therapy is not necessary and the results of
this study remain valid for clinically signi cant episodes of
atrial tachycardia.
A second limitation is that six patients were treated with
an antiarrhythmic drug for hypertension or for an arrhyth-
mia other than atrial tachycardia. It is possible that drug
therapy in these patients suppressed symptomatic atrial
tachycardia that otherwise may have occurred.
Conclusion
Radiofrequency catheter ablation of atrial tachycardia
has a lower success rate than catheter ablation of AV nodal
reentrant tachycardia or accessory pathways,2 a higher re-
currence rate after ablation (5% to 18%),7 ,8 and a higher
potential for multifocality.2 Furthermore, mapping of atrial
tachycardias is tedious when the episodes of induced tachy-
cardia are nonsustained.9 For these reasons, and because the
majority of patients with inducible atrial tachycardia after
slow pathway ablation remain asymptomatic, we recom-
mend deferring catheter ablation or drug therapy for the
inducible atrial tachycardia, unless there is documentation
that the atrial tachycardia is clinically signi cant.
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1 22/F None RAOD Yes 340 No IST 36
2 37/M None RAOD Yes 330 No PAF 96
3 52/F None RAOD No 290 No AVNRT 63
4 60/M MVR PAS Yes 460 No AT 350
5 48/F None PAS Yes 460 No PAC 100
6 71/M None PAS No 540 Yes AT 14
AT 5 atrial tachycardia; AVNRT 5 AV nodal reentrant tachycardia; CL 5 cycle length; IST 5 inappropriate sinus tachycardia; MVR 5 mitral valve
repair; PAC 5 premature atrial complex; PAF 5 paroxysmal atrial  brillation; PAS 5 programmed atrial stimulation; RAOD 5 right atrial overdrive
pacing; RFA 5 radiofrequency ablation.
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